Vistagen surges 30% on FDA fast track status for nasal spray for depression
- The U.S. Food and Drug Administration (FDA) granted fast track designation to Vistagen (NASDAQ:VTGN) PH10 nasal spray to treat major depressive disorder (MDD) in adults.
- The company said the FDA's decision was backed by results of Vistagen's nonclinical studies and three prior clinical studies of PH10, including a phase 2a trial in MDD.
- Last week, Vistagen received the FDA's greenlight to proceed with an early-stage trial of PH10.
- VTGN +31.73% to $0.16 premarket Dec. 6